Relmada Therapeutics, Inc. (FRA:4E2)

Market Cap	419.55M +2,264.2%
Revenue (ttm)	n/a
Net Income	-54.20M
EPS	-0.74
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	3.820
Previous Close	3.820
Day's Range	3.820 - 3.820
52-Week Range	0.500 - 6.500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 6, 2026

About Relmada Therapeutics

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docetaxel, which is in Phase 2 clinical trial for patients with aggressive forms of non-muscle invasive bladder cancer; and Sepranolone, a neurosteroid epimer of allopregnanolone, which is Phase 2b-ready for the potential treatment of prader-willi syndrome, tourette syndrome, excessive tremor, and other diseases related to excessive ...

• Industry: Pharmaceutical Preparations
• Founded: 2004
• Employees: 17
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 4E2

Financial Performance

Financial numbers in USD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 26, 2026

Data Sources Report a data error